| Literature DB >> 30872715 |
Delia Taverner1, Silvia Paredes1, Raimon Ferré2, Lluís Masana2, Antoni Castro2, Joan-Carles Vallvé3.
Abstract
We aimed to study arterial stiffness variables in patients with rheumatoid arthritis (RA), specifically considering their associations with path model mediation analysis. We examined arterial stiffness expressed by the pulse wave velocity (PVW), augmentation index (AIx), distensibility, and clinical and biochemical characteristics in a cohort of 214 RA patients. Variable associations were analysed using multivariate linear regression analysis. We also used path model mediation analysis for PWV variable. Our results indicate that age, systolic blood pressure (SBP), and body mass index (BMI) were significantly associated with PWV, and collectively accounted for 32% of PWV variability. The parallel mediation analysis showed that SBP and BMI accounted for 21% and 7% (a total of 28%) of the total effect of age on PWV, respectively, indicating a partial mediation effect. The associated variables with AIx were age and tender joint count, while those with distensibility were BMI and sex, overall accounting for 16.5% and 4.7% of the variation in AIx and distensibility, respectively. We observed no associations of arterial stiffness with inflammatory variables, disease activity and duration, or cholesterol levels. In conclusion, in our population of RA patients, age is the most important variable that determines the increase in PWV. We have also shown that a significant proportion of the negative effects of age on PWV occurs through increases in SBP and BMI. In our study, lipid and inflammation variables were not associated with an increase in arterial stiffness.Entities:
Mesh:
Year: 2019 PMID: 30872715 PMCID: PMC6418197 DOI: 10.1038/s41598-019-41069-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Path model diagram with the results of parallel mediation analysis. Path model showing the effect of age on the PWV as mediated simultaneously by SBP and BMI. Total β effect (path c) represents the effect of age on PWV with no mediators in the model. Direct β effect (path c’) represents the effect of age on PWV when SBP and BMI mediators are included in the model. Indirect effects (path a1b1 or path a2b2) represent the effect of age on PWV through SBP or BMI respectively. The figure shows unstandardized β regression coefficients (*p < 0.05, **p < 0.001, ***p < 0.0001).
General characteristics of RA patients.
| RA (n = 214) | |
|---|---|
|
| |
| Sex-female (%, n) | 64.5 (138) |
| Age (years) | 58 (12) |
| Body mass index (kg/m2) | 27.8 (5.9) |
| Waist circumference (cm) | 93 (15) |
| Systolic blood pressure (mmHg) | 137 (21) |
| Diastolic blood pressure (mmHg) | 81 (12) |
| LDL cholesterol (mg/dL) | 119 (31) |
| HDL cholesterol (mg/dL) | 66 (19) |
| Triglycerides (mg/dL) | 105 (55) |
| Glucose (mg/dL) | 95 (23) |
| Current smoker (%, n) | 26.2 (56) |
| Hypertension (%, n) | 60.3 (129) |
| Diabetes mellitus (%, n) | 11.7 (25) |
| Dyslipidemia (%, n) | 41.1 (88) |
|
| |
| Disease duration (years) | 9.4 (9.1) |
| DAS28 | 3.5 (1.3) |
| Disease Remission (%,n) | 27.1 (58) |
| Low disease activity (%, n) | 18.7 (41) |
| Moderate disease activity (%, n) | 44.4 (95) |
| High disease activity (%, n) | 9.8 (21) |
| HAQ | 0.45 (0.52) |
| Rheumatoid factor + (%, n) | 72.4 (155) |
| ACPA + (%, n) | 81.3 (174) |
| ESR (mm/h) | 37 (26) |
| CRP (mg/dL) | 0.72 (0.83) |
| Fibrinogen (mg/dL) | 443 (97) |
|
| |
| DMARDs | 75.2 (161) |
| Biological agent | 20.1 (43) |
| NSAIDs | 57 (122) |
| Corticosteroids | 50.9 (109) |
HAQ; health assessment questionnaire index, ACPA; citrullinated anti-cyclic peptide antibodies, ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, DAS28; disease activity score, DMARDs; disease-modifying antirheumatic drugs, NSAIDs; non-steroidal anti-inflammatory drugs.
Correlations of arterial stiffness variables with clinical and analytical variables.
| Pulse wave velocity | Distensibility | Augmentation index | |||||||
|---|---|---|---|---|---|---|---|---|---|
| r | β | p | r | β | p | r | β | p | |
| Disease duration (years) | 0.118 | 0.001 | 0.048 | −0.01 | 0.001 | 0.447 | 0.146 | 0.073 | 0.050 |
| DAS28 | 0.010 | 0.001 | 0.442 | −0.036 | 0.001 | 0.305 | −0.008 | −0.028 | 0.463 |
| HAQ | 0.031 | 0.006 | 0.33 | −0.087 | 0.006 | 0.108 | −0.029 | −0.254 | 0.374 |
| ESR (mm/h) | 0.212 | 0.001 | 0.001 | −0.139 | 0.001 | 0.024 | 0.049 | 0.009 | 0.293 |
| CRP (mg/dL) | 0.118 | 0.016 | 0.047 | −0.065 | 0.016 | 0.177 | −0.142 | −0.843 | 0.056 |
| Fibrinogen (mg/dL) | 0.071 | 0.0008 | 0.159 | −0.015 | 0.0001 | 0.415 | 0.005 | 0.0001 | 0.477 |
| HDLc (mg/dL) | 0.006 | 0.0001 | 0.465 | 0.018 | 0.0001 | 0.401 | 0.240 | 0.059 | 0.003 |
| LDLc (mg/dL) | 0.156 | 0.001 | 0.013 | −0.043 | 0.001 | 0.272 | 0.079 | 0.012 | 0.188 |
| Triglycerides (mg/dL) | 0.132 | 0.0001 | 0.031 | −0.009 | 0.0001 | 0.448 | −0.008 | −0.001 | 0.463 |
| Age | 0.514 | 0.005 | 0.0001 | −0.140 | 0.005 | 0.023 | 0.371 | 0.152 | 0.0001 |
| BMI (kg/m2) | 0.298 | 0.006 | 0.0001 | −0.181 | 0.006 | 0.005 | 0.059 | 0.055 | 0.254 |
| SBP (mmHg) | 0.447 | 0.002 | 0.0001 | −0.038 | 0.002 | 0.295 | 0.185 | 0.040 | 0.019 |
| DBP (mmHg) | 0.192 | 0.002 | 0.003 | −0.140 | 0.002 | 0.023 | 0.059 | 0.021 | 0.255 |
| Glucose (mg/dL) | 0.199 | 0.001 | 0.002 | −0.060 | 0.001 | 0.199 | −0.001 | 0.0001 | 0.494 |
| HbA1c (%) | 0.177 | 0.024 | 0.006 | 0.001 | 0.024 | 0.492 | 0.013 | 0.065 | 0.443 |
r; spearman coefficient; p; p value; β; univariate linear regression estimates.
DAS28; disease activity score, HAQ; health assessment questionnaire index, ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, HDLc; High-density lipoprotein cholesterol, LDLc; Low-density lipoprotein cholesterol, BMI; Body mass index, SBP; systolic blood pressure. Data for AIx was only available for 128 AR patients.
Parallel mediator model summary.
| Pulse Wave velocity (m/s) | |||||
|---|---|---|---|---|---|
| β | SE | P value | 95% CI | ||
| Lower | Upper | ||||
|
| |||||
| Total effect (path c) | 0.096 | 0.0123 | 0.0001 | ||
| Direct effect (path c’) | 0.069 | 0.013 | 0.0001 | ||
| Age to SBP (path a1) | 0.775 | 0.11 | 0.0001 | ||
| Age to BMI (path a2) | 0.076 | 0.032 | 0.0182 | ||
| Total indirect effect | 0.0268 | 0.0125 | 0.0425 | ||
|
| |||||
| Direct effect (path b1) | 0.025 | 0.0075 | 0.001 | ||
| Indirect effect (path a1b1) | 0.0203 | 0.0082 | 0.0338 | ||
|
| |||||
| Direct effect (path b2) | 0.085 | 0.026 | 0.001 | ||
| Indirect effect (path a2b2) | 0.0065 | 0.0006 | 0.0149 | ||
Data are obtained from PROCESS macro-application (37). Total β effect (path c) represents the effect of age on PWV with no mediators in the model. Direct β effect (path c’) represents the effect of age on PWV when SBP and BMI mediators are included in the model. Indirect effects (path a1b1 or path a2b2) represent the effect of age on PWV through SBP or BMI respectively.
SBP: systolic blood pressure; BMI: body mass index; SE: standard error; β: linear regression estimates.